Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4736 ± tremelimumab vs platinum chemotherapy in unresectable stage IV urothelial carcinoma
CTR20170135Phase 3Terminated
- Sponsor
- MedImmune
- Start
- Feb 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, tremelimumab in transitional cell carcinoma (TCC), sponsored by MedImmune. Started Feb 2017; status: terminated.
02
Drugs
durvalumabtremelimumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20170135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170135.